Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Bristol Myers sees return to growth for Opdivo, tops estimates

07/28/2021 | 08:11am EDT
FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge

(Reuters) - Bristol Myers Squibb Co reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.

Excluding one-time items, Bristol Myers reported earnings of $4.3 billion, or $1.93 per share, beating analyst estimates of around $4.2 billion and $1.89 per share, according to IBES data from Refinitiv.

Bristol Myers reported second quarter revenues of $11.7 billion, 16% higher than in the same period last year, driven in part by sales of Opdivo that exceeded $1.9 billion for the quarter, 16% higher than in the quarter ended June 30, 2020.

"The highlight that is driving that strong performance is Opdivo and its return to growth," said David Elkins, Bristol-Myers' chief financial officer.

Opdivo revenues benefitted from approvals in new tumor types and its increasing use as an initial treatment for advanced lung cancer, Elkins said.

Bristol Myers' second quarter results mark a reversal from its performance last year, where a 3% decline in sales of Opdivo contributed to lower-than-expected earnings.

Bristol Myers still expects full-year earnings in the range of $7.35 to $7.55 a share

In the second quarter, Bristol Myers announced two deals with biotechs Agenus Inc and Eisai Co to develop and market new cancer drugs and it expects to do additional deals to build out its portfolio of medicines, Elkins said.

"With the financial flexibility we have, we are really focusing on replenishing and diversifying the portfolio," Elkins said. He added that Bristol Myers is more likely to engage in deals for individual products as opposed to large scale corporate M&A.

Revlimid, the blockbuster cancer drug Bristol Myers acquired in its $74 billion deal for Celgene in 2019, will lose some of its U.S. patent exclusivity in 2022, putting pressure on the company to add new products to its pipeline.

The COVID-19 pandemic continues to affect Bristol Myers but the drugmaker saw a significant improvement in the second quarter in many of its businesses, said Chief Commercial Officer Chris Boerner.

(Reporting by Carl O'Donnell; editing by Richard Pullin)

By Carl O'Donnell


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AGENUS INC. -3.45% 5.31 Delayed Quote.66.98%
BRISTOL-MYERS SQUIBB COMPANY 1.14% 58.36 Delayed Quote.-5.92%
Latest news "Economy & Forex"
01:37aPhilippines' Synergy Grid sets guidance for up to $386 million share sale
RE
01:35aPhilips lowers outlook as recall, parts shortages bite
RE
01:26aIndonesia's 2021 crude palm oil exports seen sharply lower - industry body
RE
01:23aGSK : Berenberg cuts target price to 1540p from 1625p
RE
01:23aTESCO : For Britain's chicken farmers, Brexit and COVID brew a perfect storm
RE
01:14aChina's economy stumbles on power crunch, property woes
RE
01:13aHow green champion Sweden could end up exporting its carbon sins
RE
01:13aJapan must issue bonds to fund pandemic-relief steps, PM Kishida says
RE
01:00aU.S. refiners set for higher earnings on fuel demand strength
RE
12:59aOil prices climb as COVID recovery, power generators stoke demand
RE
Latest news "Economy & Forex"